ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 16 of 45
Up
JMBS 2023, 8(1): 122–132
https://doi.org/10.26693/jmbs08.01.122
Clinical Medicine

Influence of Angiotensin II Type 1 Receptor Gene Polymorphism on the Effectiveness of Antihypertensive Therapy in Patients with Hypertension Disease who Suffered Myocardial Infarction according to the Results of Long-Term Follow-Up

Kolesnyk T. V., Fursa O. V.
Abstract

The purpose of the study was to evaluate the effectiveness of antihypertensive therapy based on the data of daily blood pressure monitoring in patients with hypertension and a history of myocardial infarction, taking into account the A1166C polymorphism of the angiotensin II type 1 receptor gene, based on the results of long-term follow-up. Materials and methods. The study included 36 men with arterial hypertension of the 1st to 3rd degree who had suffered a myocardial infarction. The average age was 57.0 (52.0; 64.0) years, the experience of arterial hypertension – 6.3 (4.0; 15.0) years, the period after a myocardial infarction – 48.0 (12.0; 144.0) months. When determining the A1166C polymorphism of the angiotensin II type 1 receptor gene, patients were divided into 3 groups: group 1 consisted of 18 (50%) patients with the AA genotype, group 2 included 12 (33.3%) patients with the AС genotype, and group 3 – 6 (16.7%) patients with СС genotype of angiotensin II type 1 receptor gene. Daily blood pressure monitoring was carried out at the beginning of the study and after 38 months. Results and discussion. At the beginning of the study, based on the results of daily blood pressure monitoring, it was found that in the group as a whole, the levels of systolic blood pressure and diastolic blood pressure, the pressure load index – the diastolic blood pressure time index corresponded to the target values according to the median, but the pressure load indices for systolic blood pressure exceeded the normal range. Against the background of long-term antihypertensive therapy, a reliable decrease in systolic blood pressure levels was established for all time periods of the day, especially during the daytime. A significant decrease in the values of the pressure load indices was established – the time index of systolic blood pressure at daytime (delta -10.49%, which was -27.9%) and the area index of systolic blood pressure at daytime (delta -34.89 mm Hg x h, which was -32.0%) (p <0.05). When analyzing the effectiveness of long-term antihypertensive therapy depending on the A1166C polymorphism of the angiotensin II type 1 receptor gene, it was established that the highest percentage of achieving the target blood pressure level (66.7%) in combination with the normalization of the circadian blood pressure rhythm was determined in patients with the AA genotype of the AGTR1 gene. Among patients with AC genotype, 33.3% reached the target blood pressure levels, but it was not possible to achieve normalization of blood pressure variability and pathological patterns of the circadian rhythm of blood pressure persisted, which are signs of a prognostically unfavorable course of the disease. Among patients with CC genotype of the AGTR1 gene, against the background of long-term treatment, 33.3% achieved the target level of blood pressure, in general, the group normalized the degree of nocturnal decrease in blood pressure, but only a decrease in the levels of systolic blood pressure and diastolic blood pressure during the day in combination with increased values of pressure load indices was observed, which indicates insufficiently effective control of arterial hypertension. Conclusion. During the long-term observation of patients with hypertension and a history of myocardial infarction, an assessment of the effectiveness of antihypertensive therapy was carried out taking into account the A1166C polymorphism of the AGTR1 gene based on the results of daily blood pressure monitoring

Keywords: arterial hypertension, history of myocardial infarction, daily blood pressure monitoring, A1166C polymorphism of the angiotensin II type 1 receptor gene

Full text: PDF (Ukr) 347K

References
  1. Stan zdorov'ya narodu Ukrayiny ta medychnoyi dopomogy tretynnogo rivnya [State of health of the people of Ukraine and tertiary level medical care: guide]. Posibnyk. Za red VM Kovalenko, VM Kornatskogo. K; 2019. 224 s. [Ukrainian]
  2. Sem'yaniv MM. Faktory ryzyku ta polimorfizm gena AGTR1 (1166A>C) u khvorykh na esentsiynu arterialnu gipertenziyu [Risk factors and polymorphism of the AGTR1 gene (1166A>C) in patients with essential arterial hypertension]. Bukovynskyy medychnyy visnyk. 2020;4(96);99-10. [Ukrainian]. https://doi.org/10.24061/2413-0737.XXIV.4.96.2020.109
  3. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. PMID: 26551272. PMCID: PMC4689591. https://doi.org/10.1056/NEJMoa1511939
  4. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357. PMID: 32370572. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
  5. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018 Sep;39(33):3021-3104. PMID: 30165516. https://doi.org/10.1093/eurheartj/ehy339
  6. Saik OV, Demenkov PS, Ivanisenko TV, Bragina EY, Freidin MB, Goncharova IA, et al. Novel candidate genes important for asthma and hypertension comorbidity revealed from associative gene networks. BMC Med Genomics. 2018 Feb 13;11(Suppl 1):15. PMID: 29504915. PMCID: PMC6389037. https://doi.org/10.1186/s12920-018-0331-4
  7. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner v2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019 Nov 1;35(22):4851-4853. PMID: 31233103. PMCID: PMC6853652. https://doi.org/10.1093/bioinformatics/btz469
  8. Rekomendatsiyi Asotsiatsiyi kardiologiv Ukrayiny z diagnostyky ta likuvannya khronichnoyi sertsevoyi nedostatnosti [Recommendations of the Association of Cardiologists of Ukraine on diagnosis and treatment of chronic heart failure]. K: 2017. [Ukrainian]. Available from: https://strazhesko.org.ua/upload/rekomendaciyi-hsn-a6-ost.pdf
  9. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. PMID: 31504418. https://doi.org/10.1093/eurheartj/ehz455
  10. Liu Y, Kong X, Jiang Y, Zhao M, Gao P, Cong X, et al. Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan. Int J Hypertens. 2022 Mar 19;2022:7677252. PMID: 35345577. PMCID: PMC8957473. https://doi.org/10.1155/2022/7677252
  11. Praktychni rekomendatsiyi shchodo vedennya patsiyentiv z arterialnoyi gipertenziyi [Practical recommendations for the management of patients with arterial hypertension]. [Ukrainian]. Available from: https://health-ua.com/article/61729-praktichn-rekomendatc-shodo-vedennya-patcntv-zarteralnoyu-gpertenzyu
  12. Adapted from Juhani Knuuti, William Wijns and all, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The European Society of Cardiology 2019. Peredrukovano z: Ukrayinskyy kardiologichnyy zhurnal. 2020;1 z dozvolu redaktsiyi: http://practice.ucardioj.com.ua. [Ukrainian]. Available from: http://ucardioj.com.ua/index.php/UJC/article/view/209
  13. Nakaz MOZU № 2857 vid 23 grudnya 2021 r. Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomogy «Stabilna ishemichna khvoroba sertsya» [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care "Stable coronary heart disease"]. [Ukrainian]. Available from: https://moz.gov.ua/uploads/7/35063-dn_2857_23_12_2021_dod.pdf
  14. Nabir dlya vydilennya DNK z riznykh byolohichnykh preparativ obemom 100 mkl [A set for the isolation of DNA from various biological preparations with a volume of 100 μl]. Instruktsyya NeoPrep50 DNA. K; 2013. [Ukrainian]
  15. International Society for Chronobiology; American Association of Medical Chronobiology and Chronotherapeutics; Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk; Spanish Society of Atherosclerosis; Romanian Society of Internal Medicine; Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013 Apr;30(3):355-410. PMID: 23517220. HTTPS://DOI.ORG/10.3109/07420528.2013.750490
  16. Antomonov MY. Matematychna obrobka y analyz medyko-byologichnykh dannykh [Mathematical processing and analysis of medical and biological data]. 2 vyd. K: MYTs «Medynform»; 2018. 579 s. [Ukrainian]
  17. Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, Porreca E. Prognostic Value of Nondipping and Morning Surge in Elderly Treated Hypertensive Patients With Controlled Ambulatory Blood Pressure. Am J Hypertens. 2017 Feb;30(2):159-65. PMID: 27838624. https://doi.org/10.1093/ajh/hpw145
  18. Kotseva K, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018. PMID: 27638542. https://doi.org/10.1177/2047487316667784
  19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. PMID: 34458905. https://doi.org/10.1093/eurheartj/ehab484
  20. Zaytseva M.M. Osoblyvosti likuvannya khvorykh na arterialnu gipertenziyu z suputnoyu nealkogolnoyu zhyrovoyu khvoroboyu pechinky: rol A1166S polimorfizmu gena retseptora angiotenzynu II 1-go typu [Features of the treatment of patients with arterial hypertension with accompanying non-alcoholic fatty liver disease: the role of the A1166C polymorphism of the angiotensin II type 1 receptor gene]. Medytsyna sogodni i zavtra. 2014;4(65):50-58. [Ukrainian]
  21. Holmes L, Lim A, Comeaux CR, Dabney KW, Okundaye O. DNA Methylation of Candidate Genes (ACE II, IFN-γ, AGTR 1, CKG, ADD1, SCNN1B and TLR2) in Essential Hypertension: A Systematic Review and Quantitative Evidence Synthesis. Int J Environ Res Public Health. 2019;16(23):4829. HTTPS://DOI.ORG/10.3390/ijerph16234829
  22. Worapaka M, Williams GH. Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms. Endocr Rev. 2019 Jun;40(3):825-856. PMID: 30590482. PMCID: PMC6936319. https://doi.org/10.1210/er.2018-00071
  23. Verdecchia P. Interpretation of ambulatory blood pressure profile: a practical approach for clinicians. J Clin Exp Cardiol. 2013;4(7). https://doi.org/10.4172/2155-9880.1000e128